Indication: Non-small cell lung cancer (NSCLC)
Technology Platform: Next generation GVAX vaccine “CD40LGVAX”
CBMG acquired from Blackbird Bio Finance (“BB”) University of South Florida’s (“Licensor”) next generation GVAX vaccine’s (“CD40LGVAX”) related technologies and know-how. As part of the transaction, CBMG is the exclusive global licensee of the Licensor’s related technologies and know-how, the progeny manufacturing rights with access to a master vaccine bank originating from the University of South Florida (“USF”). VIEW PRESS RELEASE HERE
CD40LGVAX is a vaccine in which irradiated allogeneic lung adenocarcinoma cells are combined with a bystander cell line transfected with hCD40L and hGM-CSF. The key differentiator is the transfection of the bystander cell line with GM-CSF and CD40L. Both GM-CSF and CD40L can activate dendritic cells (DC). Nivolumab, an anti-PD-1 monoclonal antibody, enhances cytotoxic T cell activity by blocking the interaction between PD-1 and its receptors. The vaccine has previously been tested in a Phase I trial, and has shown encouraging efficacy and toxicity profile. In the United States, the Food and Drug Administration (“FDA”) has approved Nivolumab for treatment of patients with melanoma and advanced squamous NSCLC who have progressed on or after platinum-based chemotherapy. About 25% to 30% of all NSCLC are squamous. By combining CD40LGVAX with an anti-PD1 monoclonal antibody, the approach is expected to further boost the body’s immune system to kill cancer cells. Given the strength of both products and potential synergistic mechanism of action, this potential combination may provide more clinical benefit to NSCLC than either product alone.
CD40LGVAX vaccine carries GM-CSF and CD40L to activate Dendritic Cell to present tumor antigen
Check Point PD-1 Antibody has proven clinical activities against a number of cancers